Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1389-1402

  Wang, Ping ^a   Mao, Yong ^a   Razo, Juan ^a   Zhou, Xiaobo ^a   Wong, Stephen T C ^a   Patel, Samir ^a   Elliott, Erin ^a   Shea, Erin ^b   Wu, Alan H B ^b   Gaber, A Osama ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CYP3A; dosing algorithm; pharmacogenomics; renal transplant; tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TACROLIMUS; YOUNG ADULT;

EID: 78149294395     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.105     Document Type: Article

References (66)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant 4(3), 378-383 (2004).
2. Staatz C, Taylor P, Tett S: Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol. Dial. Transplant 16(9), 1905-1909 (2001).
3. Mayer AD, Dmitrewski J, Squiffet JP et al.: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus multicenter renal study group. Transplantation 64(3), 436-443 (1997).
4. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Fk506 kidney transplant study group. Transplantation 63(7), 977-983 (1997).
5. Wallemacq P, Armstrong V W, Brunet M et al.: Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31(2), 139-152 (2009).
6. Benkali K, Premaud A, Picard N et al.: Tacrolimus population pharmacokinetic-pharmacogenetic ana lysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48(12), 805-816 (2009).
7. Cattaneo D, Perico N, Remuzzi G: From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am. J. Transplant 4(3), 299-310 (2004).
8. Fredericks S, Holt DW: Pharmacogenomics of immunosuppressive drug metabolism. Curr. Opin. Nephrol. Hypertens. 12(6), 607-613 (2003).
9. Burckart GJ, Liu XI: Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther. Drug Monit. 28(1), 23-30 (2006).
10. Masuda S, Inui K: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther. 112(1), 184-198 (2006).
11. De Jonge H, Naesens M, Kuypers DR: New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther. Drug Monit. 31(4), 416-435 (2009).
12. Dirks NL, Huth B, Yates CR, Meibohm B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. 42(12), 701-718 (2004).
13. Mancinelli LM, Frassetto L, Floren LC et al.: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69(1), 24-31 (2001).
14. Macphee IA, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
15. Thervet E, Anglicheau D, King B et al.: Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233-1235 (2003).
16. Macphee IA, Fredericks S, Mohamed M et al.: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79(4), 499-502 (2005).
17. Tada H, Tsuchiya N, Satoh S et al.: Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 37(4), 1730-1732 (2005).
18. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
19. Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
20. Macphee IA, Fredericks S, Tai T et al.: The infuence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant 4(6), 914-919 (2004).
21. Dai Y, Hebert MF, Isoherranen N et al.: Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 34(5), 836-847 (2006).
22. Tsuchiya N, Satoh S, Tada H et al.: Infuence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78(8), 1182-1187 (2004).
23. Zhang X, Liu ZH, Zheng JM et al.: Infuence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant 19(5), 638-643 (2005).
24. Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14(7), 471-478 (2004).
25. Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F et al.: Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc. 40(9), 2949-2951 (2008).
26. Satoh S, Kagaya H, Saito M et al.: Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br. J. Clin. Pharmacol. 66(2), 207-214 (2008).
27. Op den Buijsch RA, Christiaans MH, Stolk LM et al.: Tacrolimus pharmacokinetics and pharmacogenetics: Infuence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam. Clin. Pharmacol. 21(4), 427-435 (2007).
28. Coto E, Tavira B: Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88(Suppl. 3), S62-S67 (2009).
29. Zhao W, Elie V, Roussey G et al.: Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6), 609-618 (2009).
30. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
31. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001).
32. Anglicheau D, Verstuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14(7), 1889-1896 (2003).
33. Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74(4), 571-572 (2002).
34. Roy JN, Barama A, Poirier C, Vinet B, Roger M: CYP3A4, CYP3A5, and MDR-1 genetic infuences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16(9), 659-665 (2006).
35. Brogan IJ, Pravica V, Hutchinson IV: Genetic conservation of the immunophilin-binding domains of human calcineurin a1 and a2. Transpl. Immunol. 8(2), 139-141 (2000).
36. Alak AM: Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. Ther. Drug Monit. 19(3), 338-351 (1997).
37. Moreton M, Fredericks S, Mckeown DA et al.: CYP3A5 genotype does not infuence the blood concentration of tacrolimus measured with the Abbott immunoassay. Clin. Chem. 51(11), 2214-2215 (2005).
38. Thervet E, Loriot MA, Barbier S et al.: Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010)
39. Hesselink DA, van Schaik RH, van Agteren M et al.: CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics 18(4), 339-348 (2008).
40. Quteineh L, Verstuyft C, Furlan V et al.: Infuence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6), 546-552 (2008).
41. Ichimaru N, Takahara S, Kokado Y et al.: Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158(2), 417-423 (2001).
42. Willrich MA, Hirata MH, Genvigir FD et al.: CYP353 allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin. Chim. Acta 398(1-2), 15-20 (2008).
43. Mai I, Stormer E, Goldammer M et al.: MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J. Clin. Pharmacol. 43(10), 1101-1107 (2003).
44. Takami A, Mochizuki K, Okumura H et al.: Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int. J. Hematol. 83(1), 80-85 (2006).
45. Ginsburg PM, Thuluvath PJ: Diarrhea in liver transplant recipients: etiology and management. Liver. Transpl. 11(8), 881-890 (2005).
46. Maes BD, Lemahieu W, Kuypers D et al.: Differential effect of diarrhea on FK506 versus cyclosporine a trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am. J. Transplant 2(10), 989-992 (2002).
47. Bunnapradist S, Neri L, Wong W et al.: Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am. J. Kidney Dis. 51(3), 478-486 (2008).
48. Ziegler TR, Fernandez-Estivariz C, Gu LH, Fried M W, Leader LM: Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 124(7), 1950-1957 (2003).
49. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y: Cytochrome p450 3A4 and p-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am. J. Transplant 5(6), 1383-1391 (2005).
50. Rodrigues AC, Curi R, Britto LR et al.: Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim. Biophys Acta 1760(12), 1866-1873 (2006).
51. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-coA reductase inhibitors (statins) characterized as direct inhibitors of p-glycoprotein. Pharm. Res. 18(6), 800-806 (2001).
52. Marchesini G, Bua V, Brunori A et al.: Galactose elimination capacity and liver volume in aging man. Hepatology (Baltimore, MD) 8(5), 1079-1083 (1988).
53. Woodhouse KW, Wynne HA: Age-related changes in liver size and hepatic blood fow. The infuence on drug metabolism in the elderly. Clin. Pharmacokinet. 15(5), 287-294 (1988).
54. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF: The effect of age upon liver volume and apparent liver blood fow in healthy man. Hepatology (Baltimore, MD) 9(2), 297-301 (1989).
55. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M: Age and cytochrome p450-linked drug metabolism in humans: an ana lysis of 226 subjects with equal histopathologic conditions. Clin. Pharmacol. Ther. 61(3), 331-339 (1997).
56. Cotreau MM, von Moltke LL, Greenblatt DJ: The infuence of age and sex on the clearance of cytochrome p450 3A substrates. Clin. Pharmacokinet. 44(1), 33-60 (2005).
57. Miura M, Satoh S, Kagaya H et al.: No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur. J. Clin. Pharmacol. 65(10), 1047-1053 (2009).
58. Hesselink DA, van Gelder T, van Schaik RH: The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005).
59. Haufroid V, Wallemacq P, Vankerckhove V et al.: CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant 6(11), 2706-2713 (2006).
60. Macphee IA, Holt DW: A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 85(2), 163-165 (2008).
61. Mourad M, Mourad G, Wallemacq P et al.: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80(7), 977-984 (2005).
62. Hesselink DA, Ngyuen H, Wabbijn M et al.: Tacrolimus dose requirement in renal transplant recipients is signifcantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 56(3), 327-330 (2003).
63. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP: Increase in tacrolimus trough levels after steroid withdrawal. Transpl. Int. 16(10), 721-725 (2003).
64. Anglicheau D, Flamant M, Schlageter MH et al.: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant 18(11), 2409-2414 (2003).
65. Metcalfe S, Alexander D, Turner J: FK506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fuxes. Transpl. Int. 7 (Suppl. 1), S549-S551 (1994).
66. Metcalfe S, Alexander D, Turner J: FK506 and cyclosporin A each inhibit antigen-specifc signaling in the T cell line 171 in the absence of a calcium signal. Cell Immunol. 158(1), 46-58 (1994).